This report provides an exhaustive analysis of this transition, forecasting the technological, clinical, and commercial trajectory of the sector over the next three years (2025–2028). It posits that the integration of Tiny Machine Learning (TinyML), advanced biosensing, and novel regulatory pathways is creating a new class of medical device: one that is continuously active, privacy-preserving by design, and capable of real-time clinical intervention without reliance on internet connectivity.
Podden och tillhörande omslagsbild på den här sidan tillhör
Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av,
eller tillsammans med, Poddtoppen.
